No Data
No Data
No Data
No Data
No Data
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares have had a horrible month, losing 27% after a relatively good period beforehand. The recent drop has obliterated the annual return, with the share pri
Simply Wall StApr 27 20:39
Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Yahoo FinanceApr 25 22:34
Komo: Upgraded CytomX Therapeutics (CTMX.US) rating from reduced holdings to neutral rating.
Komo: Upgraded CytomX Therapeutics (CTMX.US) rating from reduced holdings to neutral rating.
Zhitong FinanceApr 22 20:20
JP Morgan Upgrades CytomX Therapeutics to Neutral
JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Underweight to Neutral.
BenzingaApr 22 20:18
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)
TipRanksApr 22 16:20
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersRallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by
BenzingaApr 11 04:31
No Data
No Data